Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study.
IF 4.2
3区 医学
Q2 OPHTHALMOLOGY
Ophthalmology and Therapy
Pub Date : 2026-08-01
Epub Date: 2026-06-24
DOI:10.1007/s40123-026-01431-z
引用次数: 0
Abstract
Introduction: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases. However, transient post-injection intraocular pressure elevations have raised concerns regarding potential cumulative effects on inner retinal structures, including the peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell-inner plexiform layer (mGCIP). As longitudinal evidence on the neuro-retinal structural safety of higher-dose formulations such as aflibercept 8 mg remains limited, this study evaluated 12-month changes in pRNFL and mGCIP thickness following intravitreal aflibercept 8 mg.
Methods: This single-centre, observational longitudinal cohort study included patients with nAMD treated with intravitreal aflibercept 8 mg or aflibercept 2 mg. Patients receiving aflibercept 8 mg were prospectively enrolled, while patients treated with 2 mg aflibercept were retrospectively identified. Spectral-domain optical coherence tomography was used to assess pRNFL and mGCIP thickness at baseline and at 3, 6 and 12 months. Longitudinal within-eye changes relative to baseline were analysed, alongside inter-eye comparisons with fellow untreated eyes and between-treatment group comparisons at 12 months.
Results: Thirty-eight eyes from 35 patients were included. In eyes treated with aflibercept 8 mg, mGCIP thickness remained stable throughout follow-up, with no significant changes at 3, 6 or 12 months compared with baseline. At 12 months, mGCIP thickness was comparable between aflibercept 8 mg-treated eyes and fellow untreated eyes, as well as between aflibercept 8 mg and aflibercept 2 mg-treated eyes. Similarly, pRNFL thickness showed no significant global or sectoral changes over 12 months and did not differ between treatment groups.
Conclusion: Over 12 months of follow-up, intravitreal aflibercept 8 mg was not associated with significant thinning of pRNFL or mGCIP thickness, supporting its neuro-retinal structural safety in routine clinical practice.
新血管性年龄相关性黄斑变性玻璃体内注射阿非利赛普8mg后，乳头周围视网膜神经纤维和神经节细胞层的变化：一项纵向OCT研究。
玻璃体内抗血管内皮生长因子（anti-VEGF）治疗是新生血管性年龄相关性黄斑变性（nAMD）和其他视网膜血管疾病的标准治疗方法。然而，注射后短暂的眼压升高引起了对视网膜内部结构的潜在累积效应的关注，包括乳头周围视网膜神经纤维层（pRNFL）和黄斑神经节细胞-内丛状层（mGCIP）。由于高剂量制剂如阿伯西普8mg的神经视网膜结构安全性的纵向证据仍然有限，本研究评估了阿伯西普8mg玻璃体内注射后12个月pRNFL和mGCIP厚度的变化。方法：这项单中心、观察性纵向队列研究纳入了接受阿布利赛8 mg或阿布利赛2 mg玻璃体内治疗的nAMD患者。接受阿非利西普8mg治疗的患者被前瞻性纳入研究，而接受阿非利西普2mg治疗的患者被回顾性确定。使用光谱域光学相干断层扫描评估基线、3、6和12个月时的pRNFL和mGCIP厚度。分析相对于基线的眼内纵向变化，以及12个月时与未治疗眼的眼间比较和治疗组间比较。结果：纳入35例患者38只眼。在使用阿伯西普8mg治疗的眼睛中，mGCIP厚度在整个随访期间保持稳定，与基线相比，在3、6或12个月时没有显著变化。在12个月时，阿伯西普8 mg治疗组和未治疗组的眼部mGCIP厚度相当，阿伯西普8 mg和阿伯西普2 mg治疗组的眼部mGCIP厚度相当。同样，pRNFL厚度在12个月内没有显示出显著的全球或部门变化，并且在治疗组之间没有差异。结论：经过12个月的随访，玻璃体内注射阿非利赛8mg与pRNFL或mGCIP厚度的明显变薄无关，在常规临床实践中支持其神经视网膜结构的安全性。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Ophthalmology and Therapy
OPHTHALMOLOGY-
CiteScore
4.20
自引率
3.00%
发文量
157
审稿时长
6 weeks
期刊介绍：
Aims and Scope
Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.
Rapid Publication
The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies.
Open Access
All articles published by Ophthalmology and Therapy are open access.
Personal Service
The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.
Digital Features and Plain Language Summaries
Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.
For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/
Publication Fees
Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor.
Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.
Please follow the link for further information on preprint sharing:
https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550
Copyright
Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
Contact
For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
